References
- Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009). TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther, 8, 125-30. https://doi.org/10.4161/cbt.8.2.7134
- Huang L, Schauer IG, Zhang J, et al (2011). The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer. Int J Clin Exp Pathol, 4, 644-50.
- Lee K, Chae JY, Kwak C, Ku JH, Moon KC(2010). TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology, 76, 1267-8.
- Mao X, Yu Y,Boyd LK, et al (2010). Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res, 70, 5207-12. https://doi.org/10.1158/0008-5472.CAN-09-4074
- Rubio-Briones J, Fernandez-Serra A, Calatrava A, et al (2010). Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol, 183, 2054-61. https://doi.org/10.1016/j.juro.2009.12.096
- Song FJ, Zhang BL, He M, et al (2010). Trend analysis of the incidence of prostate cancer in Tianjin between 1981 and 2004. Zhonghua Yi Xue Za Zhi, 90, 2811-4.
- Sun QP, Li LY,Chen Z, et al (2010). Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. J Mol Diag, 12, 718-24. https://doi.org/10.2353/jmoldx.2010.100002
- Sun YH (2004). Research on prostate cancer in China. Chin J Urol, 25, 77-80.
- Takai N, Miyazaki T, Fujisawa K, Nasu K, Miyakawa I (2000). Expression of c-Ets1 is associated with malignant potential in endometrial carcinoma. Cancer, 89, 2059-67. https://doi.org/10.1002/1097-0142(20001115)89:10<2059::AID-CNCR5>3.0.CO;2-3
- Tomlins SA, Mehra R,Rhodes DR, et al (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res, 66, 3396-400. https://doi.org/10.1158/0008-5472.CAN-06-0168
- Tomlins SA, Rhodes DR,Perner S, et al (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310, 644-8. https://doi.org/10.1126/science.1117679
- Weir HK, Thun MJ, Hankey BF, et al (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst, 95, 1276-99. https://doi.org/10.1093/jnci/djg040
Cited by
- TMPRSS2:ETS Fusions and Clinicopathologic Characteristics of Prostate Cancer Patients from Eastern China vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3099
- TMPRSS2-ERG gene fusion in prostate cancer pp.18047521, 2014, https://doi.org/10.5507/bp.2014.065
- Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: Focusing on Asians and Asian countries vol.22, pp.4, 2015, https://doi.org/10.1111/iju.12701
- Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue pp.1792-1082, 2015, https://doi.org/10.3892/ol.2015.3093
- ERG expression in prostate cancer: biological relevance and clinical implication vol.142, pp.8, 2016, https://doi.org/10.1007/s00432-015-2096-x
- TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer vol.37, pp.9, 2016, https://doi.org/10.1007/s13277-016-5116-9